The gap is closing between companies choosing non-viral and viral delivery methods at the discovery, preclinical and IND-enabling stages

Despite the continued dominance of viral vectors in gene therapy development, these data suggest that an increasing number of companies in the space are choosing to develop medicines employing non-viral delivery methods.